SLC5A2 and Hyperglycemia: SGLT2 inhibitors improve both fasting and postprandial hyperglycemia and increase time-in-range (TIR, proportion of time spent in the target glucose range between 70 and 180 mg/dL) assessed by continuous glucose monitoring (CGM) [14,15].